The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6447-6452

  Van Herwaarden, Antonius E ^a   Jonker, Johan W ^a   Wagenaar, Els ^a   Brinkhuis, Remco F ^a   Schellens, Jan H M ^a   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; CARCINOGEN; HETEROCYCLIC AMINE; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; COLON CANCER; CONTROLLED STUDY; DIET; DRUG TRANSPORT; HUMAN; LYMPHOMA; MOUSE; MULTIDRUG RESISTANCE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CARCINOGENS; CELL LINE; DOGS; FECES; GALLBLADDER; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; P-GLYCOPROTEIN; SWINE; TISSUE DISTRIBUTION;

EID: 0141919551     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Zheng, W., Gustafson, D. R., Sinha, R., Cerhan, J. R., Moore, D., Hong, C. P., Anderson, K. E., Kushi, L. H., Sellers, T. A., and Folsom, A. R. Well-done meat intake and the risk of breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1724-1729, 1998.
2. Felton, J. S., Knize, M. G., Shen, N. H., Lewis, P. R., Andresen, B. D., Happe, J., and Hatch, J. T. The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (Lond.), 7: 1081-1086, 1986.
3. Ito, N., Hasegawa, R., Sano, M., Tamano, S., Esumi, H., Takayama, S., and Sugimura, T. A. new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (Lond.), 12: 1503-1506, 1991.
4. Gross, G. A., Turesky, R. J., Fay, L. B., Stillwell, W. G., Skipper, P. L., and Tannenbaum, S. R. Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis (Lond.), 14: 2313-2318, 1993.
5. Wakabayashi, K., Ushiyama, H., Takahashi, M., Nukaya, H., Kim, S. B., Hirose, M., Ochiai, M., Sugimura, T., and Nagao, M. Exposure to heterocyclic amines. Environ. Health Perspect., 99: 129-133, 1993.
6. Ushiyama, H., Wakabayashi, K., Hirose, M., Itoh, H., Sugimura, T., and Nagao, M. Presence of carcinogenic heterocyclic amines in urine of healthy volunteers eating normal diet, but not in patients receiving parenteral alimentation. Carcinogenesis (Lond.), 12: 1417-1422, 1991.
7. Layton, D. W., Bogen, K. T., Knize, M. G., Hatch, F. T., Johnson, V. M., and Felton, J. S. Cancer risk of helerocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis (Lond.), 16: 39-52, 1995.
8. Manabe, S., Tohyama, K., Wada, O., and Aramaki, T. Detection of a carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (Ph1P), in cigarette smoke condensate. Carcinogenesis (Lond.), 12: 1945-1947, 1991.
9. Ishiguro, Y., Ochiai, M., Sugimura, T., Nagao, M., and Nakagama, H. Strain differences of rats in the susceptibility to aberrant crypt foci formation by 2-amino-1-methyl-6-phenylinfidazo[4,5-b]pyridine: no implication of Apc and P1a2g2a genetic polymorphisms in differential susceptibility. Carcinogenesis (Lond.), 20: 1063-1068, 1999.
10. Esumi, H., Ohgaki, H., Kohzen, E., Takayama, S., and Sugimura, T. Induction of lymphoma in CDFI mice by the food mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Jpn. J. Cancer Res., 80: 1176-1178, 1989.
11. Shirai, T., Cui, L., Takahashi, S., Futakuchi, M., Asamoto, M., Kato, K., and Ito, N. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett., 143: 217-221, 1999.
12. Imaida, K., Hagiwara, A., Yada, H., Masui, T., Hasegawa, R., Hirose, M., Sugimura, T., Ito, N., and Shirai, T. Dose-dependent induction of mammary carcinomas in female Sprague-Dawley rats with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Jpn. J. Cancer Res., 87: 1116-1120, 1996.
13. Hasegawa, R., Sano, M., Tamano, S., Imaida, K., Shirai, T., Nagao, M., Sugimura, T., and Ito, N. Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenicity in rats. Carcinogenesis (Lond.), 14: 2553-2557, 1993.
14. Sinha, R., Gustafson, D. R., Kulldorff, M., Wen, W., Cerhan, J. R., and Zheng, W. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a carcinogen in high-temperature-cooked meat, and breast cancer risk. J. Natl. Cancer Inst. (Bethesda), 92: 1352-1354, 2000.
15. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
16. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., and Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.
17. Jonker, J. W., Smit, J. W., Brinkhuis, R. F., Maliepaard, M., Beijnen, J. H., Schellens, J. H. M., and Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (Bethesda), 92: 1651-1656, 2000.
18. Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Oude Elferink, R. P. J., Rosing, H., Beijnen, J. H., and Schinkel, A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA, 99: 15649-15654, 2002.
19. Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., and Sugimoto, Y. C. 421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther., 1: 611-616, 2002.
20. Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K., Schuetz, J. D., and Schuetz, E. G. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics, 13: 19-28, 2003.
21. Dietrich, C. G., de Waart, D. R., Ottenhoff, R., Schoots, I. G., and Oude Elferink, R. P. J. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharm., 59: 974-980, 2001.
22. Dietrich, C. G., de Waart, D. R., Ottenhoff, R., Bootsma, A. H., van Gennip, A. H., and Oude Elferink, R. P. J. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (Ph1P). Carcinogenesis (Lond.), 22: 805-811, 2001.
23. Allen, J. D., van Loevezijn, A., Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G. J., and Schinkel, A. H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther., 1: 417-425, 2002.
24. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., and Borst, P. Absence of the mdr1 a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Investig., 96: 1698-1705, 1995.
25. Smit, J. W., Weert, B., Schinkel, A. H., and Meijer, D. K. F. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J. Pharmacol. Exp. Ther., 286: 321-327, 1998.
26. Evers, R., Kool, M., van Deemter, L., Janssen, H., Calafat, J., Oomen, L. C. J. M., Paulusma, C. C., Oude Elferink, R. P. J., Baas, F., Schinkel, A. H., and Borst, P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Investig., 101: 1310-1319, 1998.
27. De Bruin, M., Miyake, K., Litman, T., Robey, R., and Bates, S. E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett., 146: 117-126, 1999.
28. Kruijtzer, C. M., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., and Schellens, J. H. M. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol., 20: 2943-2950, 2002.
29. Cooray, H. C., Blackmore, C. G., Maskell, L., and Barrand, M. A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport, 13: 2059-2063, 2002.
30. Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., and Sorontino, B. P. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. USA, 99: 12339-12344, 2002.